# EDGAR Filing Document

**Accession Number:** 0001612042
**File Stem:** 0001193125-26-162865
**Filing Date:** 2026-4
**Character Count:** 4787
**Document Hash:** 7f15d0b83a03c2a0db009df9956b7952
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-162865.hdr.sgml**: 20260420

**ACCESSION NUMBER**: 0001193125-26-162865

**CONFORMED SUBMISSION TYPE**: 8-A12B/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260420

**DATE AS OF CHANGE**: 20260420

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ascendis Pharma A/S
- **CENTRAL INDEX KEY:** 0001612042
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36815
- **FILM NUMBER:** 26873489

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TUBORG BOULEVARD 12
- **CITY:** HELLERUP
- **PROVINCE COUNTRY:** G7
- **BUSINESS PHONE:** 45 70 22 22 44

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TUBORG BOULEVARD 12
- **CITY:** HELLERUP
- **PROVINCE COUNTRY:** G7

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-A/A** 

**(Amendment No. 1)** 

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES** 

**PURSUANT TO SECTION 12(b) OR (g) OF** 

**THE SECURITIES EXCHANGE ACT OF 1934** 

## ASCENDIS PHARMA A/S
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **The Kingdom of Denmark** | **Not Applicable** |
| **(State or other jurisdiction of incorporation or organization)** | **(I.R.S. Employer Identification No.)** |

---

---

| | |
|:---|:---|
| **Tuborg Boulevard 12, DK-2900 Hellerup, Denmark** | **Not Applicable** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Securities to be registered pursuant to Section 12(b) of the Act:** 

---

| | |
|:---|:---|
| **Title of each class**<br> **to be registered** | **Name of each exchange on which**<br> **each class is to be registered** |
| **Ordinary shares, DKK 1 nominal value per share** | **The Nasdaq Stock Market LLC** |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

**Securities Act registration statement or Regulation A offering statement file number to which this form relates:<u> </u>**

**<u>None</u>** 

**Securities to be registered pursuant to Section 12(g) of the Act:<u> </u>**

**<u>None</u>** 

------

**EXPLANATORY NOTE** 

Ascendis Pharma A/S (the "Registrant") is filing this Amendment No. 1 (the "Amendment No. 1") to its registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1612042/000119312515019449/d855781d8a12b.htm) originally filed with the Securities and Exchange Commission (the "Commission") on January 26, 2015 (the "Existing Form 8-A"), in connection with the mandatory exchange of American depositary shares for ordinary shares. The Amendment No. 1 amends and restates in its entirety the Existing Form 8-A previously filed by the Registrant.

**INFORMATION REQUIRED IN REGISTRATION STATEMENT** 

**Item 1. Description of Registrant's Securities to be Registered.** 

The Registrant hereby incorporates by reference the description of its ordinary shares, nominal value DKK 1 per share, included in [Exhibit 2.3](http://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-ex2_3.htm) to the Registrant's Annual Report on Form 20-F for the year ended December 31, 2025 (File No. 001-36815), filed with the Commission on February 11, 2026.

**Item 2. Exhibits.** 

Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

------

**SIGNATURE** 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ASCENDIS PHARMA A/S** | **ASCENDIS PHARMA A/S** |
| Date: April 20, 2026 | By: | /s/ Michael Wolff Jensen |
|  |  | Michael Wolff Jensen |
|  |  | Executive Vice President, Chief Legal Officer |

---